Charles Schwab
EVMN icon

Charles Schwab’s Evommune Inc EVMN Stock Holding History

Charles Schwab’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
133,072
+38,124
+40% +$886K ﹤0.01% 2827
2026
Q1 		$2.18M Buy
94,948
+32,244
+51% +$729K ﹤0.01% 2698
2025
Q4 		$1.07M Buy
+62,704
New +$1.18M ﹤0.01% 2901

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Charles Schwab's EVMN Position: Q2 2026 in Review

Charles Schwab increased its Evommune Inc (EVMN) stake by 40% in Q2 2026, buying an estimated $886K and bringing the position to 133,072 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2827.

Charles Schwab first reported a position in EVMN in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.18M in Q1 2026. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Charles Schwab held 133,072 shares of Evommune Inc worth $1.77M as of Q2 2026.
  • Charles Schwab bought 38,124 Evommune Inc shares in Q2 2026, an estimated $886K.
  • Evommune Inc made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2827 holding.
  • Charles Schwab first reported a position in Evommune Inc in Q4 2025 and has held it in 3 quarters since.
  • Charles Schwab's Evommune Inc position peaked at $2.18M in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.